BioStem Technologies, Inc. announces the integration of an experienced national sales force to accelerate its commercial expansion and strengthen its position across hospital settings. Barry Hassett has been promoted to Chief Commercial Officer. The company closed a definitive asset purchase agreement with BioTissue Holdings Inc., acquiring the BioTissue surgical and wound care business. The acquisition includes the Neox® and Clarix® product lines, and significant GPO contracts. The agreement involves an upfront cash payment of $15 million, with potential milestone payments up to $25 million. The acquired assets generated $29 million in sales in 2025.

Read more at GlobeNewswire: BioStem Technologies Advances Entry into the Acute Wound